RecruitingPhase 1NCT06040541

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors

Sponsor

Revolution Medicines, Inc.

Enrollment

604 participants

Start Date

Sep 7, 2023

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors Colorectal Cancer (CRC)

Summary

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called RMC-9805 in patients with solid tumors (cancers in organs or tissues) that have a specific genetic mutation called KRAS G12D. This mutation is found in many pancreatic, colon, and lung cancers. **You may be eligible if...** - Your cancer has been confirmed to have a KRAS G12D genetic mutation - Your cancer is locally advanced or has spread (metastatic) - You have already received standard treatments and your cancer has progressed - You are in generally good health (ECOG performance status 0 or 1) **You may NOT be eligible if...** - You have a primary brain tumor or active brain metastases - You have significant digestive problems that would prevent you from absorbing an oral medication - You have previously received a KRAS G12D inhibitor or any direct RAS-targeted therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRMC-9805

Oral Tablets

DRUGRMC-6236

Oral Tablets

Locations(17)

University of California, Davis Comprehensive Cancer Center

Sacramento, California, United States

Smilow Cancer Hospital (Yale University)

New Haven, Connecticut, United States

Florida Cancer Specialists

Sarasota, Florida, United States

Lee Moffitt Cancer Center

Tampa, Florida, United States

Johns Hopkins University

Baltimore, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

NYU Langone

New York, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Duke Cancer Center

Durham, North Carolina, United States

Carolina BioOncology Institute

Huntersville, North Carolina, United States

The Christ Hospital

Cincinnati, Ohio, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

Sarah Cannon Research Institute at Mary Crowley

Dallas, Texas, United States

University of Texas, MD Anderson Cancer Center

Houston, Texas, United States

START

San Antonio, Texas, United States

NEXT Oncology Virginia

Fairfax, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06040541

Related Trials

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

NCT0714001615 locations

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT066944541 location

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497254 locations

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037204 locations

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

NCT0725540410 locations